Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22%) were in the older group (age ≥75) and 302 (78%) in the younger group (age <75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6% vs. 57.9%, p = 0.03) and extramedullary disease (22% vs. 40%, p = 0.02). There were no significant differences in rates of any-grade CRS (52% vs. 59%, p = 0.27), any-grade ICANS (19% vs. 13%, p = 0.12), and overall response rate (62% vs. 53%, p = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration.
Authors
- Jack Khouri (ORCID: https://orcid.org/0000-0002-2473-6528)
- Mahmoud Gaballa (ORCID: https://orcid.org/0000-0002-3928-6590)
- Sandra P. Susanibar-Adaniya (ORCID: https://orcid.org/0000-0003-0703-2518)
- Beatrice M. Razzo (ORCID: https://orcid.org/0000-0001-9904-3315)
- Faiz Anwer (ORCID: https://orcid.org/0000-0001-6914-7439)
- Aimaz Afrough (ORCID: https://orcid.org/0000-0003-2645-8557)
- Jenny Bhurtel (ORCID: https://orcid.org/0000-0001-5670-0186)
- Nabil E. Omar (ORCID: https://orcid.org/0000-0001-8291-7987)
- Surbhi Sidana (ORCID: https://orcid.org/0000-0003-3288-7614)
- Rahul Kumar Banerjee (ORCID: https://orcid.org/0000-0003-3781-5441)
- Danai Dima (ORCID: https://orcid.org/0000-0002-3587-7975)
- Shonali Midha (ORCID: https://orcid.org/0000-0003-4948-5507)
- Andrew J. Cowan (ORCID: https://orcid.org/0000-0002-1880-7094)
- Hitomi Hosoya (ORCID: https://orcid.org/0000-0003-0475-9666)
- Andrew J. Portuguese (ORCID: https://orcid.org/0000-0003-1010-4578)
- Shahzad Raza (ORCID: https://orcid.org/0000-0002-2739-2265)
- Alfred L. Garfall (ORCID: https://orcid.org/0000-0003-2791-5748)
- Lekha Mikkilineni
- Larry D. Anderson (ORCID: https://orcid.org/0000-0002-6531-9595)
- Leyla Shune (ORCID: https://orcid.org/0000-0003-1650-1873)
- Utkarsh Goel (ORCID: https://orcid.org/0000-0003-1663-0325)
- Shebli Atrash (ORCID: https://orcid.org/0000-0003-4547-7534)
- Shambavi Richard (ORCID: https://orcid.org/0000-0003-0274-4292)
- Adriana Rossi (ORCID: https://orcid.org/0009-0004-9914-5628)
- Doris K. Hansen (ORCID: https://orcid.org/0000-0002-9813-3578)
- Hans Chulhee Lee (ORCID: https://orcid.org/0000-0001-8545-3292)
- Tiffany Richards
- Joseph P. McGuirk (ORCID: https://orcid.org/0000-0002-0539-4796)
- Aishwarya Sannareddy
- Douglas W. Sborov (ORCID: https://orcid.org/0000-0003-4268-2698)
- Gurbakhash Kaur (ORCID: https://orcid.org/0000-0002-2510-6536)
- Krina K. Patel (ORCID: https://orcid.org/0000-0002-8894-027X)
- Ciara L. Freeman (ORCID: https://orcid.org/0000-0002-0662-6480)
- Kelley Julian (ORCID: https://orcid.org/0000-0002-2111-2461)
- Wenli Dong (ORCID: https://orcid.org/0009-0005-1978-0371)
- Peter Michael Voorhees (ORCID: https://orcid.org/0000-0003-1661-718X)
- Oren Pasvolsky (ORCID: https://orcid.org/0000-0001-9193-0059)
- Chenyu Lin (ORCID: https://orcid.org/0000-0002-4542-4232)
- Daniel Schrum (ORCID: https://orcid.org/0000-0002-9779-2723)
- Megan M. Herr (ORCID: https://orcid.org/0000-0001-5768-9396)
- Masooma Rana (ORCID: https://orcid.org/0000-0003-1731-085X)
- Christopher J. Ferreri (ORCID: https://orcid.org/0000-0003-2997-4856)
- Alex Lieberman-Cribbin (ORCID: https://orcid.org/0009-0004-5462-4991)
- Ariel Felipe Grajales-Cruz (ORCID: https://orcid.org/0000-0003-0999-1771)
- James A. Davis (ORCID: https://orcid.org/0000-0001-7978-1652)
- Melissa Alsina (ORCID: https://orcid.org/0000-0003-4946-823X)
- Mariola Vazquez‐Martinez (ORCID: https://orcid.org/0009-0007-2643-7840)
- Lei Feng (ORCID: https://orcid.org/0000-0003-1165-8046)
- Yi Lin (ORCID: https://orcid.org/0000-0002-1556-6416)
- Shaun DeJarnette
- Frances Cervoni
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Medical University of South Carolina (US)
- Duke University (US)
- Palo Alto University (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Fred Hutch Cancer Center (US)
- Levine Cancer Institute (US)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- Duke Medical Center (US)
- University of Kansas Medical Center (US)
- University School (US)
- Southwestern Medical Center (US)
- Case Western Reserve University (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1038/s41408-025-01297-7
- Citations
- 7
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.39
Funders
- National Cancer Institute
- NIH Clinical Center